TG Therapeutics challenges Roche with FDA filing for CLL drug
pharmaphorum
DECEMBER 2, 2020
The New York-based firm has requested approval for the combination of its anti-CD20 antibody ublituximab and umralisib, an oral drug that inhibits PI3K-delta and CK-1 epsilon. US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic lymphocytic leukaemia, in a challenge to Roche.
52 
Let's personalize your content